Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of cisatracurium in preparation of medicine for treating male hypogonadism

A technology of cisatracurium and hypofunction, which is applied in drug combinations, diseases, pharmaceutical formulas, etc., can solve problems such as hypertrophy, fluctuation of serum testosterone concentration, dysuria, etc., and achieve improvement of male hypogonadism, Effect of increasing testosterone levels and reversing side effects of male hypogonadism

Active Publication Date: 2022-02-01
JIAXING NO 1 HOSPITAL
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the clinical treatment of hypogonadism is mainly through testosterone supplementation therapy. However, in addition to the need for regular injections of testosterone, this therapy also has significant safety issues
Firstly, long-term quantitative supplementation of testosterone will make patients prone to acne and polycythemia; secondly, it will easily cause large fluctuations in serum testosterone concentration, which in turn will cause obvious fluctuations in the patient's mood and symptoms of delayed hypogonadism syndrome; thirdly, Patients are prone to adverse reactions such as water and sodium retention, priapism, and dysuria, and even liver and kidney function damage and prostate cancer and other diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cisatracurium in preparation of medicine for treating male hypogonadism
  • Application of cisatracurium in preparation of medicine for treating male hypogonadism
  • Application of cisatracurium in preparation of medicine for treating male hypogonadism

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] The application of cisatracurium in the preparation of medicaments for treating male hypogonadism is illustrated by taking cisatracurium against the inhibitory effect of nicotine on the synthesis of testosterone by rat adult Leydig cells.

[0032] Seven male Sprague-Dawley rats (90 days old) were killed by carbon dioxide, and the testes were taken out, and adult Leydig cells were extracted and purified, cultured in LCM medium, and grouped as follows:

[0033] 1) Treat with normal saline as blank control group;

[0034] 2) treated with 50 μM cisatracurium physiological saline solution to form the cisatracurium group;

[0035] 3) treated with 50 μM nicotine in physiological saline solution to be the nicotine group;

[0036] 4) The normal saline solution of 50 μM nicotine and 50 μM cisatracurium was treated as the joint group 1, and the testosterone level in the culture medium was measured after 12 hours of drug treatment in the above-mentioned groups. The results are shown...

Embodiment 2

[0041] The application of cisatracurium in the preparation of medicaments for treating male hypogonadism is illustrated by taking cisatracurium against the inhibitory effect of lobeline on the synthesis of testosterone by rat adult Leydig cells.

[0042] Seven male Sprague-Dawley rats (90 days old) were killed by carbon dioxide, and the testes were taken out, and adult Leydig cells were extracted and purified, cultured in LCM medium, and grouped as follows:

[0043] 1) Treat with normal saline as blank control group;

[0044] 2) treated with 50 μM cisatracurium physiological saline solution to form the cisatracurium group;

[0045] 3) treated with 50 μM lobeline in physiological saline solution to be the lobeline group;

[0046] 4) Treatment with 50 μM lobelin and 50 μM cisatracurium in physiological saline solution as combination group 2,

[0047] Measure the testosterone level in the culture medium after above-mentioned each group drug treatment 12 hours, the result sees ...

Embodiment 3

[0051] The application of cisatracurium in the preparation of drugs for increasing the testosterone content in the body is illustrated by taking the effect of cisatracurium in increasing the synthesis of testosterone by rat adult Leydig cells as an example.

[0052] Seven male Sprague-Dawley rats (90 days old) were killed by carbon dioxide, and the testes were taken out, and adult Leydig cells were extracted and purified, cultured in LCM medium, and grouped as follows:

[0053] 1) Treat with normal saline as blank control group;

[0054] 2) Treat with 5 μM cisatracurium physiological saline solution;

[0055] 3) Treat with 10 μM cisatracurium saline solution;

[0056] 4) Treat with 50 μM cisatracurium physiological saline solution;

[0057] Measure the testosterone level in the culture medium after above-mentioned each group drug treatment 12 hours, the result sees image 3 (a) shown.

[0058] image 3 In (a), the data are expressed as mean ± standard error, and the sampl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of sexual function medicines. In order to develop a new approach for treating male hypogonadism, the application of cisatracurium in the preparation of medicines for treating male hypogonadism is disclosed, and at the same time, the cis-atracurium is disclosed. The application of atracurium in the preparation of the medicine for resisting the side effect of male hypogonadism caused by nicotine, and the application of cisatracurium in the preparation of the medicine for increasing the testosterone content in the body. In the present invention, cisatracurium has the ability to stimulate the synthesis of testosterone in the testicular interstitial cells of organisms, has an improvement or therapeutic effect on low testosterone in serum and / or testis, and has a positive effect on the side effects of male hypogonadism caused by nicotine. At the same time, cisatracurium has been proved to be safe and has low side effects after clinical anesthesia, so it is the same as the existing testosterone injection method, providing a new way to improve male hypogonadism.

Description

technical field [0001] The invention relates to the technical field of sexual function medicines, in particular to the application of cisatracurium in the preparation of medicines for treating male hypogonadism. Background technique [0002] Male hypogonadism is a disease of hypogonadism caused by the lack or reduction of androgen or the inability to exert its function. The main function of Leydig cells is to synthesize testosterone, which is the main source of androgen in males. The hypofunction of hormone synthesis and secretion in adult Leydig cells will lead to androgen deficiency in the body. At present, the clinical treatment of hypogonadism is mainly through testosterone supplementation therapy. However, in addition to the need for regular injections of testosterone, this therapy also has significant safety issues. Firstly, long-term quantitative supplementation of testosterone will make patients prone to acne and polycythemia; secondly, it will easily cause large f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4725A61P15/08
CPCA61K31/4725A61P15/08
Inventor 姚明倪超波葛仁山徐龙生
Owner JIAXING NO 1 HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com